<?xml version="1.1" encoding="UTF-8" standalone="yes"?><xml><head><creation_date>D:20040823141004+02'00'</creation_date><modification_date>D:20040823141021+02'00'</modification_date><initial_authorization>False</initial_authorization><pdf_file>EU-1-99-100_h_dec_9.pdf</pdf_file></head><body><section><header>en</header><p>commission of the european communities</p><p>brussels, 17-viii-2004 c(2004)3246 
 not for publication</p></section><section><header>commission decision of 17-viii-2004 
 on the renewal of the marketing authorisation for &quot;cetrotide - cetrorelix (as 
 acetate)&quot; the medicinal product for human use granted by decision c(1999)939</header><p>only the english text is authentic</p></section><section><header>en  
   en</header></section><section><header>en  
   en</header></section><section><header>commission decision of 17-viii-2004 
 on the renewal of the marketing authorisation for &quot;cetrotide - cetrorelix (as 
 acetate)&quot; the medicinal product for human use granted by decision c(1999)939 
 (text with eea relevance)</header><p>the commission of the european communities, having regard to the treaty establishing the european community,</p><p>
 having regard to council regulation (eec) no 2309/93 of 22 july 1993 laying down 
 community procedures for the authorization and supervision of medicinal products for 
 human and veterinary use and establishing a european agency for the evaluation of 
 medicinal products
 1, as amended by commission regulation (ec) no 649/982, and in particular article 10(2) thereof, 
 having regard to the application submitted by serono europe ltd., on 13 january 2004, 
 under article 13(1) of regulation (eec) no 2309/93 with a view to the renewal of the 
 marketing authorisation for the medicinal product &quot;cetrotide - cetrorelix (as acetate)&quot; 
 having regard to the opinion of the european agency for the evaluation of medicinal 
 products, formulated by the committee for proprietary medicinal products on 24 march 
 2004, 
 whereas: 
 (1)</p><p>after consideration by the agency of a dossier containing up-to-date information 
 on pharmacovigilance, it appears that the medicinal product &quot;cetrotide - 
 cetrorelix (as acetate)&quot; entered in the community register of medicinal products 
 under nos eu/1/99/100/001-003 and authorised by commission decision 
 c(1999)939 of 13 april 1999, complies with the requirements set out in directive 
 2001/83/ec of the european parliament and of the council of 6 november 2001 
 on the community code relating to medicinal products for human use
 3 as amended by directive 2002/98/ec
 4 and by directive 2003/63/ec5. (2)</p><p>the marketing authorisation which expires on 15 april 2004 should therefore be 
 renewed.</p><p>
 1 oj l 214, 24. 8. 1993, p. 1. 2 oj l 88, 24.3.1998, p. 7. 3 oj l 311, 28.11.2001, p. 67. 4 oj l 33, 8.2.2003, p. 30. 5 oj l 159, 27.6.2003, p. 46.</p></section><section><header>en  
   en</header><p>(3) the measures provided for in this decision are in accordance with the opinion of 
 the standing committee on medicinal products for human use, 
 has adopted this decision: 
 article 1 the marketing authorisation granted by decision c(1999)939 of 13 april 1999 which expires on 15 april 2004 is renewed. 
 article 2 decision c(1999)939 is amended as follows:</p><p>
 a) annex i is replaced by annex i to this decision;</p><p>
 b) annex ii is replaced by annex ii to this decision;</p><p>
 c) annex iii (a and b) is replaced by annex iii to this decision. 
 article 3 the period of validity of the renewed authorization shall be five years from 15 april 2004.</p><p>
 article 4 this decision is addressed to serono europe ltd., 56, marsh wall, london e14 9tp, united kingdom. 
 done at brussels, 17-viii-2004 
 for the commission olli rehn</p><p>
 member of the commission</p></section></body></xml>